TYP 4.55% 2.1¢ tryptamine therapeutics limited

Buy Recommendation, page-68

  1. 22,297 Posts.
    lightbulb Created with Sketch. 485

    PLEXOVAL I study disrupted by the Covid-19 response

    - PLEXOVAL is a world-first study using a cellfree, platelet-derived exosome product, manufactured using Exopharm's proprietary LEAP Technology, for wound healing
    - COVID-19 has impacted the progress of Exopharm’s PLEXOVALI human trial, and will likely reduce recruitment numbers, neither Cohorts 1 and 2 will fully recruit, and the study report will be delayed
    - Initial results from Cohort2 may be available in the coming months
    - Planning is underway, for the follow-on study, using allogeneic(off-the-shelf) Plexaris
    http://exopharm.com/wp-content/uploads/2020/04/72._20.04.01-Plexoval-update-Exopharm-Ltd-ASX_EX1.pdf
 
watchlist Created with Sketch. Add TYP (ASX) to my watchlist
(20min delay)
Last
2.1¢
Change
-0.001(4.55%)
Mkt cap ! $22.87M
Open High Low Value Volume
2.2¢ 2.2¢ 2.1¢ $4.354K 203.0K

Buyers (Bids)

No. Vol. Price($)
9 1202944 2.0¢
 

Sellers (Offers)

Price($) Vol. No.
2.1¢ 104 1
View Market Depth
Last trade - 10.15am 03/09/2024 (20 minute delay) ?
TYP (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.